A Cyclometalated Iridium(III) Complex Exerts High Anticancer Efficacy via Fatty Acid Beta-Oxidation Inhibition and...

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Metabolic Pathways

Background:

• Lipids play a significant role in cancer development, driving interest in therapies targeting lipid metabolism.
• Cisplatin resistance is a major challenge in pancreatic cancer treatment.

Purpose of the Study:

• To identify novel compounds targeting lipid metabolism for cancer therapy.
• To investigate the anticancer potential of cyclometalated iridium complexes in MIA PaCa-2 cells.
• To evaluate the efficacy of a novel iridium complex in overcoming cisplatin resistance.

Main Methods:

• Screening of cyclometalated iridium complexes for antiproliferation activity.
• Analysis of fatty acid and sphingolipid metabolism regulation.
• In vitro assessment of cisplatin resistance reversal.
• In vivo evaluation of Ir2@F127 carriers in a xenograft model.

Main Results:

• Identified cyclometalated iridium complex (Ir2) with potent antiproliferation activity against MIA PaCa-2 cells.
• Ir2 simultaneously regulates fatty acid and sphingolipid metabolism.
• Ir2 demonstrates efficacy in overcoming cisplatin resistance in vitro.
• Ir2@F127 carriers show effective in vivo tumor treatment with minimal side effects.

Conclusions:

• Ir2 is the first reported cyclometalated iridium complex to target lipid metabolism in MIA PaCa-2 cells.
• This study provides a novel anticancer mechanism for cyclometalated iridium complexes.
• Ir2 represents a promising therapeutic candidate for pancreatic cancer treatment.